Adoption of Abiraterone and Enzalutamide by Urologists.
Journal
Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
07
03
2019
revised:
29
04
2019
accepted:
01
05
2019
pubmed:
29
5
2019
medline:
17
1
2020
entrez:
29
5
2019
Statut:
ppublish
Résumé
To investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists. Using the Medicare Part D Public Use Files from 2013 to 2016, we identified total abiraterone and enzalutamide prescriptions 2013-2016 and urologists who prescribed moderate to high volumes of these drugs. We then characterized the urologist practices of those urologists according to practice context (eg, single-specialty group) using data from the Centers for Medicare and Medicaid Services, and the geographic distribution of those providers. We found abiraterone prescriptions increased from 71,423 in 2013 to a peak of 100,371 in 2015 and enzalutamide prescriptions continued to increase from 29,572 in 2013 to 100,980 in 2016. Prescriptions by urologists increased between 2013 and 2016 while prescriptions by other specialties plateaued. The number of moderate-high prescribing urologists increased from 98 (abiraterone) and 22 (enzalutamide) in 2013, to 301 (abiraterone) and 671 (enzalutamide) by 2016 with 1063 unique urologists prescribing moderate-high volumes of either drug between 2013 and 2016. Among urologists who prescribe androgen deprivation therapy, 5% were moderate-high prescribers of abiraterone and 12% of enzalutamide in 2016. The majority of moderate-high prescribing urologists were in single-specialty groups (70%). Urologists are increasingly prescribing oral therapies for metastatic castration-resistant prostate cancer. Understanding the distribution of urologists specializing in castration-resistant prostate cancer therapeutics will help guide future interventions to optimize the care for this important patient population.
Identifiants
pubmed: 31136769
pii: S0090-4295(19)30452-2
doi: 10.1016/j.urology.2019.05.012
pmc: PMC6711811
mid: NIHMS1029673
pii:
doi:
Substances chimiques
Androstenes
0
Benzamides
0
Nitriles
0
Phenylthiohydantoin
2010-15-3
enzalutamide
93T0T9GKNU
abiraterone
G819A456D0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
176-183Subventions
Organisme : NCI NIH HHS
ID : F32 CA232332
Pays : United States
Organisme : AHRQ HHS
ID : R01 HS025707
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA180984
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
J Palliat Med. 2018 Jun;21(6):780-788
pubmed: 29649396
J Oncol Pract. 2017 Aug;13(8):e694-e702
pubmed: 28628393
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
Prostate Cancer Prostatic Dis. 2013 Mar;16(1):1-6
pubmed: 22751145
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
Arch Surg. 2005 Sep;140(9):873-8; discussion 878-80
pubmed: 16172296
JAMA Netw Open. 2019 Apr 5;2(4):e192589
pubmed: 31002323
Rev Urol. 2003;5 Suppl 2:S48-52
pubmed: 16986047
BJU Int. 2012 Aug;110(3):328-35
pubmed: 22712568
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Urology. 2013 Jul;82(1):48-52
pubmed: 23676360
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
J Urol. 2015 May;193(5):1617
pubmed: 25895801
J Natl Cancer Inst. 2006 Jun 21;98(12):839-45
pubmed: 16788157
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
J Urol. 2016 May;195(5):1444-1452
pubmed: 26498056
J Pain Symptom Manage. 2018 Apr;55(4):1196-1215.e5
pubmed: 29221845